Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Nektar Therapeutics
NKTR | US
1.39
USD-0.02
-1.42%
NKTR | US
About Nektar Therapeutics
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
1.39
Open
1.44
High
1.44
Low
1.38
Nektar Therapeutics a biopharmaceutical company focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255 an IL-15 receptor agonist which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals Inc. The company was incorporated in 1990 and is headquartered in San Francisco California.
View LessNKTR | US
Risk
71.9
Sharpe
1.54
Luna's Score
57/100
Recommendation
Hold
Luna says (NKTR | US)
What's Working
Positive Momentum
Low Market Beta (-0.4 to 0.8)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Weak Operating Margin (< 10%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
58.6%1 month
71.9%3 months
68.2%6 months
78.9%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
3.26
Debt to equity
2.76
Debt to assets
0.64
Ent. to EBITDA
-6.50
Ent. to rev.
1.08
PEG
3.22
Other Fundamentals
EBITDA
-128.69M
MarketCap
255.87M
MarketCap(USD)
255.87M
Div. yield
-
Op. margin
-155.33
Erngs. growth
-
Rev. growth
14.60
Ret. on equity
-128.02
Short ratio
8.50
Short perc.
5.08
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.25
Range1M
0.38
Range3M
0.42
Volumes: Market Activity
Rel. volume
0.50
Price X volume
894.61K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -6.50 | - | Cheaper |
| Ent. to Revenue | 1.08 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.26 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 68.16 | - | Par |
| Debt to Equity | 2.76 | -1.23 | Expensive |
| Debt to Assets | 0.64 | 0.25 | Expensive |
| Market Cap | 255.87M | - | Emerging |
